Kura Oncology, Inc.

NASDAQ:KURA

Biotechnology

Healthcare
$7.34 +0.73%

+$0.07 today

Market cap
$674.39M
Beta
0.36
P/E (TTM)
-2.9
EPS (TTM)
-$3.32
52W Low $5.45High $12.49

Volume 2.46M

Average 1.66M

Income Statement

Follow revenue through to earnings.

Revenue

$67.48M

FY 2025 · Annual

+25.2% YoY

Operating Income

-$303.63M

FY 2025 · Annual

Net Income

-$278.67M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00053.88M67.48M
Cost of Revenue00849K057K
Gross Profit00(849K)53.88M67.43M
Gross Margin———100.0%99.9%
Research & Development84.72M92.81M115.24M169.97M251.07M
Selling, General & Admin46.54M47.05M50.57M77.11M119.98M
Operating Expenses131.26M139.87M164.96M247.08M371.06M
Depreciation & Amortization558K759K849K848K1.03M
EBITDA(129.49M)(134.85M)(150.23M)(169.5M)(275.83M)
EBITDA Margin———-314.6%-408.7%
Operating Income(131.26M)(139.87M)(165.8M)(193.2M)(303.63M)
Operating Margin———-358.5%-449.9%
Interest Income1.21M4.25M14.72M22.85M26.77M
Interest Expense414K229K1.55M1.62M1.51M
Other Income / Expenses792K4.03M13.17M21.23M25.26M
Income Before Tax(130.47M)(135.84M)(152.63M)(171.97M)(278.37M)
Pre-Tax Margin———-319.1%-412.5%
Income Tax Expense0002.02M297K
Net Income(130.47M)(135.84M)(152.63M)(173.98M)(278.67M)
Net Margin———-322.9%-412.9%
EPS (Basic)(1.97)(2.03)(2.08)(2.02)(3.18)
EPS (Diluted)(1.97)(2.03)(2.08)(2.02)(3.18)
Weighted Avg Shares66.35M66.99M73.23M86.16M87.68M
Weighted Avg Shares (Diluted)66.35M66.99M73.23M86.16M87.68M

KURA Earnings Waterfall · TTM

NASDAQ:KURA · Revenue to Net Income

Key Ratios

EPS$-3.35
Gross Margin95.3%
Net Margin-414.6%
P/E Ratio-2.5
P/S Ratio40.7

Analysis

$71.6M of revenue converted into -$294.6M of net income for the selected period. Gross margin is 95.3% and net margin is -414.6%, showing how much revenue survives after costs and taxes. EPS is $-3.35, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
S-3ASRS-3ASR filingNov 10, 2026
8-KCurrent reportNov 10, 2026
10-QQuarterly reportNov 10, 2026
SC 13G/ASC 13G/A filingOct 27, 2026
4Statement of changes in beneficial ownershipSep 29, 2026

How much revenue does KURA generate?

Kura Oncology, Inc. (KURA) reported $67.48M of revenue in fiscal 2025.

Is KURA profitable?

Kura Oncology, Inc. (KURA) reported -$278.67M of net income, with a net margin of -412.9%.